Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO UC 303 maintenance study of ontamalimab in moderate to severe ulcerative colitis
NL-OMON50472Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in autoimmune colitis (3 arms), sponsored by Takeda. Started Feb 2019; status: completed.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON50472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50472.